Sanuwave Health (NASDAQ:SNWV) Releases Earnings Results, Misses Estimates By $0.03 EPS

Sanuwave Health (NASDAQ:SNWV) announced its earnings results on Tuesday. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03), FiscalAI reports. Sanuwave Health had a negative return on equity of 141.56% and a net margin of 26.64%.The company had revenue of $9.62 million for the quarter, compared to analyst estimates of $9.60 million.

Sanuwave Health Stock Up 14.4%

NASDAQ SNWV traded up $2.31 during trading on Wednesday, reaching $18.35. 80,692 shares of the company’s stock were exchanged, compared to its average volume of 72,604. The company has a current ratio of 1.38, a quick ratio of 1.05 and a debt-to-equity ratio of 10.08. Sanuwave Health has a fifty-two week low of $15.35 and a fifty-two week high of $46.58. The company’s fifty day simple moving average is $19.17 and its 200-day simple moving average is $25.74. The firm has a market capitalization of $157.73 million, a PE ratio of -113.01 and a beta of 1.37.

Institutional Trading of Sanuwave Health

Institutional investors have recently made changes to their positions in the stock. Corient Private Wealth LLC purchased a new position in Sanuwave Health during the fourth quarter valued at approximately $257,000. Praetorian PR LLC lifted its position in Sanuwave Health by 1,436.2% in the 4th quarter. Praetorian PR LLC now owns 265,000 shares of the company’s stock worth $7,908,000 after buying an additional 247,750 shares in the last quarter. Bridgeway Capital Management LLC boosted its stake in shares of Sanuwave Health by 76.3% during the 4th quarter. Bridgeway Capital Management LLC now owns 39,279 shares of the company’s stock valued at $1,172,000 after buying an additional 17,000 shares during the period. Barclays PLC grew its holdings in shares of Sanuwave Health by 12.7% during the 4th quarter. Barclays PLC now owns 11,610 shares of the company’s stock valued at $346,000 after acquiring an additional 1,306 shares in the last quarter. Finally, Stifel Financial Corp purchased a new position in shares of Sanuwave Health during the 4th quarter valued at $5,291,000. 42.53% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have issued reports on SNWV. Roth Mkm restated a “buy” rating and set a $47.00 price objective (down from $53.00) on shares of Sanuwave Health in a report on Monday, March 30th. Weiss Ratings raised shares of Sanuwave Health from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Friday, March 27th. Zacks Research lowered shares of Sanuwave Health from a “hold” rating to a “strong sell” rating in a report on Monday, March 30th. Finally, Wall Street Zen lowered shares of Sanuwave Health from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $51.00.

About Sanuwave Health

Sanuwave Health, Inc is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company’s lead product, the dermaPACE® system, holds clearance from the U.S.